Glyoxalase 1 and its Role in Metabolic Syndrome

乙二醛酶 1 及其在代谢综合征中的作用

基本信息

  • 批准号:
    10656054
  • 负责人:
  • 金额:
    $ 41.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-01 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

Abstract The overall goal of this proposal is to determine the role of glyoxalase 1 (GLO1) in the pathogenesis of obesity, Type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD). Greater than 34 million Americans have diabetes, and another 88 million are considered pre-diabetic. This is largely attributed to the prevalence of obesity, with 72% of American adults currently classified as overweight or obese. Among the comorbidities associated with T2D, over 70% of patients have NAFLD. Epidemiological studies have linked high fructose consumption with obesity, T2D, and NAFLD. This proposal identifies GLO1 as pro-NAFLD/obesogenic gene. Using CRISPR-Cas9, we have generated GLO1 knockout mice. When fed a high-fat high sucrose diet, these mice display significantly blunted weight gain, restored glucose tolerance, and reduced hepatic steatosis compared to wild-type counterparts. GLO1 is a ubiquitously expressed enzyme that detoxifies the glycolytic by- product, methylglyoxal (MGO). When GLO1 activity is disrupted, MGO levels increase, resulting in long-lived protein post-translational modifications. We have shown that MGO serves as a metabolic sensor for nutrient flux, regulating glycolytic output and transcriptional responses to sugar. Thus, we hypothesize that GLO1 is a pro- NAFLD/obesogenic gene, reducing MGO and removing the brakes on metabolism. We will test this hypothesis by addressing the following three Specific Aims: In Specific Aim 1 we will quantify the impact of Glo1 on whole- body energetics and hepatic lipid metabolism using a 16-week chow- or high-fat high-sucrose diet. We will quantify lean vs. fat mass, energy expenditure, and total activity. Hepatic fatty acid oxidation and mitochondrial respiration will be quantified in primary hepatocytes. Lastly, lipogeneic genes will be assessed using RNA-seq. In Specific Aim 2 we will determine the impact of Glo1 on intestinal fructose metabolism. The intestine is a primary site of fructose metabolism. Stable isotope labeling via 13C6-fructose oral gavage will be used to quantify intestinal, hepatic, muscle, adipose, and circulating fructose metabolites. This approach will quantitatively determine how Glo1 regulates intestinal carbohydrate metabolism, a previously unexplored area of research. Finally, in Specific Aim 3, we will confirm that MGO-derived histone PTMs regulate transcriptional responses to metabolism in vivo. Site-specific canonical and MGO-derived PTMs will be quantified in each tissue/cohort. Putative reader domains will be identified for MG-H1 histone modifications. Lastly, liver, intestine, muscle, adipose, and pancreas will be subjected to RNA-seq and ATAC-seq. This approach will determine the global epigenomic landscape across multiple tissues in a physiologically relevant model for obesity, T2D and NAFLD. Collectively, this proposal will combine mechanistic biochemistry with a multi-omics approach to determine the mechanisms by which GLO1 propagates disease progression.
摘要 这项提议的总体目标是确定乙二醛酶1(GLO1)在肥胖发病机制中的作用。 2型糖尿病(T2D)和非酒精性脂肪肝(NAFLD)。超过3400万美国人 另有8800万人被认为是糖尿病前期。这在很大程度上归因于 肥胖,目前有72%的美国成年人被归类为超重或肥胖。在合并症中 与T2D相关,超过70%的患者患有NAFLD。流行病学研究表明,高果糖 肥胖、T2D和NAFLD的消费。该建议将GLO1确定为NAFLD前/肥胖基因。 使用CRISPR-Cas9,我们已经产生了GLO1基因敲除小鼠。当喂食高脂肪高蔗糖饮食时,这些 小鼠体重增加明显减慢,糖耐量恢复,肝脏脂肪变性减轻。 与野生型的同类相比。GLO1是一种普遍表达的酶,通过以下方式解毒糖酵解- 产品甲基乙二醛(MGO)。当GLO1活动中断时,MGO水平会增加,从而导致长寿 蛋白质翻译后修饰。我们已经证明,MGO是营养流量的新陈代谢传感器, 调节糖酵解的输出和对糖的转录反应。因此,我们假设GLO1是一个专业- NAFLD/肥胖基因,减少MGO,消除代谢刹车。我们将检验这一假设 通过处理以下三个具体目标:在具体目标1中,我们将量化全球一体化对整个世界的影响-- 身体能量和肝脏脂肪代谢,使用16周的食物或高脂肪高蔗糖饮食。我们会 量化精瘦与脂肪的质量、能量消耗和总活动量。肝脂肪酸氧化与线粒体 呼吸作用将在原代肝细胞中进行量化。最后,将使用RNA-seq来评估脂肪生成基因。 在具体目标2中,我们将确定Glo1对肠道果糖代谢的影响。肠道是一种 果糖代谢的主要部位。通过13C6-果糖口服稳定同位素标记将用于定量 肠道、肝脏、肌肉、脂肪和循环中的果糖代谢物。这一方法将在数量上 确定Glo1如何调节肠道碳水化合物代谢,这是一个以前从未探索过的研究领域。 最后,在特定的目标3中,我们将确认MGO衍生的组蛋白PTMS调节转录反应 体内代谢。将在每个组织/队列中量化特定部位的经典性和MGO来源的PTM。 将确定MG-H1组蛋白修饰的假定阅读器结构域。最后是肝、肠、肌肉, 脂肪,胰腺将受到RNA-SEQ和ATAC-SEQ的影响。这一方法将决定全球 在肥胖、T2D和NAFLD的生理相关模型中,跨多个组织的表观基因组景观。 总的来说,这项提案将结合机械性生物化学和多组学方法来确定 GLO1传播疾病进展的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James J Galligan其他文献

352 - Mitochondrial Proteins Are Highly Adducted Targets of Endogenously Generated Lipid Electrophiles in LPS-Activated RAW264.7 Macrophages
  • DOI:
    10.1016/j.freeradbiomed.2014.10.548
  • 发表时间:
    2014-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    William N Beavers;Kristie L Rose;James J Galligan;Keri A Tallman;Salisha S Hill;Stephen B Milne;David S Myers;Pavlina Ivanova;Xiaojing Wang;Bing Zhang;H Alex Brown;Ned A Porter;Lawrence J Marnett
  • 通讯作者:
    Lawrence J Marnett
4-HNE Significantly Alters L-FABP Structural and Functional Dynamics
  • DOI:
    10.1016/j.freeradbiomed.2011.10.298
  • 发表时间:
    2011-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Rebecca L Smathers;Philip Reigan;Kristofer S Fritz;James J Galligan;Colin T Shearn;Dennis R Petersen
  • 通讯作者:
    Dennis R Petersen
29 - Histones Are Major Targets for Modification by Glucose-Derived Methylglyoxal
  • DOI:
    10.1016/j.freeradbiomed.2015.10.066
  • 发表时间:
    2015-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    James J Galligan;Michelle Mitchener;Tina Wang;Orrette Wauchope;Kristie Rose;David Spiegel;Lawrence Marnett
  • 通讯作者:
    Lawrence Marnett
382 - Epigenetics and Oxidative Stress: Establishing a Link through Histone Adduction
  • DOI:
    10.1016/j.freeradbiomed.2014.10.062
  • 发表时间:
    2014-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    James J Galligan;William N Beavers;Kristie Rose;Lawrence J Marnett
  • 通讯作者:
    Lawrence J Marnett
Reactive Aldehyde 4-Hydroxynonenal Inhibits Mitochondrial Sirt3 Deacetylase Activity
  • DOI:
    10.1016/j.freeradbiomed.2010.10.221
  • 发表时间:
    2010-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Kristofer S Fritz;James J Galligan;Rebecca L Smathers;James R Roede;Colin T Shearn;Philip Reigan;Dennis R Petersen
  • 通讯作者:
    Dennis R Petersen

James J Galligan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James J Galligan', 18)}}的其他基金

Establishing Glyoxalase 2 as a Viable Target for the Treatment of Disease
将乙二醛酶 2 确立为治疗疾病的可行靶点
  • 批准号:
    10640181
  • 财政年份:
    2020
  • 资助金额:
    $ 41.38万
  • 项目类别:
Establishing Glyoxalase 2 as a Viable Target for the Treatment of Disease
将乙二醛酶 2 确立为治疗疾病的可行靶点
  • 批准号:
    10415990
  • 财政年份:
    2020
  • 资助金额:
    $ 41.38万
  • 项目类别:
Establishing Glyoxalase 2 as a Viable Target for the Treatment of Disease
将乙二醛酶 2 确立为治疗疾病的可行靶点
  • 批准号:
    10027084
  • 财政年份:
    2020
  • 资助金额:
    $ 41.38万
  • 项目类别:
Establishing Glyoxalase 2 as a Viable Target for the Treatment of Disease [Equipment Supplement]
将乙二醛酶 2 确立为治疗疾病的可行靶点 [设备补充]
  • 批准号:
    10383972
  • 财政年份:
    2020
  • 资助金额:
    $ 41.38万
  • 项目类别:
Establishing Glyoxalase 2 as a Viable Target for the Treatment of Disease
将乙二醛酶 2 确立为治疗疾病的可行靶点
  • 批准号:
    10210412
  • 财政年份:
    2020
  • 资助金额:
    $ 41.38万
  • 项目类别:
Modification of PDI by 4-HNE and 4-ONE and its Role in Ethanol-Induced ER Stress
4-HNE 和 4-ONE 对 PDI 的修饰及其在乙醇诱导的 ER 应激中的作用
  • 批准号:
    8130540
  • 财政年份:
    2010
  • 资助金额:
    $ 41.38万
  • 项目类别:
Modification of PDI by 4-HNE and 4-ONE and its Role in Ethanol-Induced ER Stress
4-HNE 和 4-ONE 对 PDI 的修饰及其在乙醇诱导的 ER 应激中的作用
  • 批准号:
    7752658
  • 财政年份:
    2009
  • 资助金额:
    $ 41.38万
  • 项目类别:

相似海外基金

Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
  • 批准号:
    2867610
  • 财政年份:
    2023
  • 资助金额:
    $ 41.38万
  • 项目类别:
    Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
  • 批准号:
    BB/W009633/1
  • 财政年份:
    2022
  • 资助金额:
    $ 41.38万
  • 项目类别:
    Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2021
  • 资助金额:
    $ 41.38万
  • 项目类别:
    Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
  • 批准号:
    459043
  • 财政年份:
    2021
  • 资助金额:
    $ 41.38万
  • 项目类别:
    Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2020
  • 资助金额:
    $ 41.38万
  • 项目类别:
    Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10561642
  • 财政年份:
    2019
  • 资助金额:
    $ 41.38万
  • 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2019
  • 资助金额:
    $ 41.38万
  • 项目类别:
    Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
  • 批准号:
    2243045
  • 财政年份:
    2019
  • 资助金额:
    $ 41.38万
  • 项目类别:
    Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10359032
  • 财政年份:
    2019
  • 资助金额:
    $ 41.38万
  • 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
  • 批准号:
    428988
  • 财政年份:
    2019
  • 资助金额:
    $ 41.38万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了